The 100,000 Genomes Project

Similar documents
The 100,000 Genomes Project Harnessing the power of genomics for NHS rare disease and cancer patients

NIHR Supporting collaboration in life sciences research

Your Health Topic : Genomics and Clinical Practice How genetics is improving care for patients

Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine

Health Science in the NHS:

Genomics and personalised prevention

Fighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program

Mainstreaming Cancer Genetics (MCG) Information Pack

Myriad Genetics Corporate Presentation 6/4/13

100,000 Genomes Project Update: The Cancer Programme Cancer Testing Strategy & NHS Genomic Medicine Service

COST ACTION CA IDENTIFYING BIOMARKERS THROUGH TRANSLATIONAL RESEARCH FOR PREVENTION AND STRATIFICATION OF COLORECTAL CANCER (TRANSCOLOCAN)

Research opportunities in UK Biobank

An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution

The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve

Implications for public health research. Professor Bernie Hannigan Director - Research, Translation & Innovation

COST ACTION CA IDENTIFYING BIOMARKERS THROUGH TRANSLATIONAL RESEARCH FOR PREVENTION AND STRATIFICATION OF COLORECTAL CANCER (TRANSCOLOCAN)

Rare Disease Research and the UK 100,000 Genome Project

University of Pittsburgh Cancer Institute UPMC CancerCenter. Uma Chandran, MSIS, PhD /21/13

Session 4 Rebecca Poulos

ACCELERATING PROGRESS THROUGH COLLABORATION ACCELERATOR AWARD CASE STUDIES

Session 4 Rebecca Poulos

Networking Clinical Trials Anna Shevlin, Clinical Trial Liaison Officer

Commissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013

Academic Clinical Fellowship in Respiratory Medicine

Moorfields Research and Innovation. Participating in research at Moorfields Eye Hospital NHS Foundation Trust. hope trust care

Dr Graeme Suthers: The genetic basis of cancer

IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM

Type 1 Research Today

International Cancer Genome Consortium The ARGO Project

Potential Opportunities for Collaboration with Pancreatic U01s

The use of diagnostic FFPE material in cancer epidemiology research

NHS Innovation Accelerator. Economic Impact Evaluation Case Study: Sapientia 1. BACKGROUND

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges

REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN MOLECULAR AND DIAGNOSTIC PATHOLOGY (PDipMDPath)

UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource

The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw

What do blood cancer patients want? (And what do we need and expect too?)

NIHR Leeds Clinical Research Facility Patient and Public Involvement Strategy

Certificate of Advanced Studies in Personalized Molecular Oncology

The Cancer Genome Atlas & International Cancer Genome Consortium

Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018

An Overview of Health Economics Data and Expertise in Cancer

Personalized medecine Biomarker

BRANCHED-CHAIN AMINO ACIDS FOUND TO REGULATE THE DEVELOPMENT AND PROGRESSION OF CANCER

SNOMED CT EXPO 2017 Bratislava, 19 October 2017

Greater Manchester Genomics Medicine Centre 100,000 genomes project - cancer newsletter No 2 March 2017

Genomics in the Kidney Clinic

Allied Healthcare Professionals Module

Funding Opportunities for Public Health Research

Georgia Cancer Quality Information Exchange

Developing effective ctdna testing services for lung cancer. Executive summary

Cancer survival by stage at diagnosis in Wales,

Health & Social Care Research Strategy

Medical Training Initiative Post Paediatric Oncology Fellow Retrieval. Job Description Lead Clinician Dr Emma Ross

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

School of Improvement Supporting trainees from Students to Consultants

NCRI Biomarkers & Imaging CSG Cell-free DNA workshop

pat hways Medtech innovation briefing Published: 20 September 2017 nice.org.uk/guidance/mib120

End of Grant Report. Registered Charity

External Quality Assurance in Genetics Laboratories

Implementing pharmacogenomics in Europe incentives & challenges

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

Speakers. Text to be added

Research and Development

NHS England Diabetes Programme Update June 2018

Big data vs. the individual liver from a regulatory perspective

Paediatrics and Neuro-development MIC Theme 7

Survival in Teenagers and Young. Adults with Cancer in the UK

Karen Brown (University of Leicester)

Personalising medicine and mainstreaming genomics: the impact on nursing

Diet, Nutrition, Physical Activity and Cancer The Future Steven K. Clinton, M.D., Ph.D.

100,000 genomes RD Validation and Reporting Working Groups - Overview - Dom McMullan Chair Association for Clinical Genomic Science

STRATEGIC PLAN

14 delegates from a variety of specialities attended the one-day workshop, held at Imperial College London.

Importance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine

Biomarkers: An approach to targeting SMARCB1-deficient sarcomas

Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

What EU research policy can do for conditions such as chronic pain?

Clinical trials updates: current and future cholangiocarcinoma trials

Structured Pathology Reporting of Cancer Newsletter

National Prostate Cancer Audit. Bill Cross June 2015

NCIN Conference Feedback 2015

Funding research for the future

BARDA INFLUENZA PROGRAM OVERVIEW

Identification and clinical validation of biomarkers for drug resistance.

Translating MRS into clinical benefit for children with brain tumours

Engaging People Strategy

The Wistar Institute is an international leader in biomedical

National Jewish Health, the Nation s Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT

ASBMR. Institute of Musculoskeletal Health and Arthritis (IMHA) Dr. Hani El-Gabalawy Scientific Director Canadian Institutes of Health Research

IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM

State of ICD 11. Robert Jakob, WHO

Personalised Medicine in Practice. Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil

Grand Challenge and other funding opportunities at Cancer Research UK. Jamie Meredith, 9 th Dec 15

Translating Duke Health. Accelerating discovery and its translation

The Intermountain Oncology Clinical Program: Present and Future

Screening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery

Occupational Health in the 11 th Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD11)

Transcription:

The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London

Genomics England mission 100,000 whole genome sequences in NHS patients with rare inherited disease, cancers and pathogens from the NHS in England Whole Genome Sequencing Generate health and wealth Legacy of infrastructure, human capacity and capability World leaders in the application of Genomic Medicine for healthcare

Rare Disease adding future value <5% of the population or about 5/10,000 people 7000 rare diseases Working on 146 disorders Detailed and genomically primed phenotyping Diagnostics genomic, imaging, pathology Human Phenotype Ontology Disease progression WGS 30X National Rare Disease Registry

Cancer adding future value Disease of disordered genomes Drugs target. Tumour heterogeneity, Evolution of cancer, Stratified medicine Lung, breast, colon, prostate, ovary and, Leukaemia Rare and Childhood Cancers, unknown primary Sarcoma, Renal Molecular Pathology Sequential biopsy of cancer WGS at 75x somatic and 30x germline

Infections and Pathogens

Creating the Innovative Platform for Future Health & Wealth 11 Wave 1 NHS Genomic Medicine Centres Rare diseases, cancers and pathogens Broad consent, characteristics, molecular pathology and samples NIHR Biosample Centre DNA & multi omics Repository Sequencing Centre Wellcome Trust 27m Refreshable identifiable Clinical Data Life course registry Linked to anonymised Whole Genome Sequence Oxford Big Data Primary Care Hospital episodes Cancer Registries Rare Disease Registries Infectious Disease Mortality data Patient entry Fire wall Patient data stays in safe haven MRC 24m Research Data Infrastructure Sequential builds of pseudonymised data and WGS Safe haven users work within Annotation & QC Scientists & SMEs Product comparison Only processed results pass outside Clinicians & Academics Training & Funders Industry GENE Consortium

Establishing infrastructure Biosample centre March 2015 11 NHS Genomic Medicine Centre Awarded 20 th December 2014 Sequencing centre 31/8/2015 MRC funded Data Centre November 2014

Innovative patient outcomes and data Patient Reported Outcomes Multi omics In rare disease and cancer NHS is funding plasma and serum sampling RNA transcriptomics, micro RNAs Epigenetics, Proteomics and metabolomics In cancer NHSE is funding Cell free circulating DNA (liquid biopsy) Sequential biopsies & WGS (trials) Potential if funds available Cancer Cell Lines for drug sensitivity, single cell physiomics or functional genomics (not funded) Experimental models Genome editing International Mouse Phenotyping Consortium MRC Harwell

Genomics England Clinical Interpretation Partnership 2500 clinicians and scientists The standard way The GeCIP way Start 2014 17 yrs?3 yrs Securing Patient Benefit

Final list of GeCIP restructured Domains Rare Disease Final Cancer of GeCIP Functional Cardiovascular Breast Electronic Records Endocrine and Metabolism Colorectal Validation and Feedback Gastroenterology and Lung Ethics and Social Science Hepatology Hearing and Sight Ovarian Functional Effects Immunology and Haematology Inherited Cancer Predisposition Prostate Childhood Solid Cancers Health Economics Machine Learning, Quantitative Methods and Functional Genomics Musculoskeletal Haematological Malignancy Population Genomics Neurological Pan Cancer Translational Research Paediatric Sepsis Functional Cross Cutting Paediatrics Renal Renal Sarcoma Stratified healthcare Respiratory skin

Building the future of genomic medicine 100,000 WGS on NHS patients and pathogens Concentrating the UK Genomics Knowledgebase in one location The NHS, academics and industry partnerships at the outset to drive Genomic Medicine into the NHS and create wealth Building the human capacity and capability Key international partnerships to add value Leave a legacy of NGS Centres, sample pipeline and biorepository, large scale data store that makes this usable by the NHS New diagnostics and therapies and opportunities for patients Contact: matina.prapa@genomicsengland.co.uk